Global Asthma Therapeutics Market Expected To Reach Over USD 46.83 Billion By The End Of 2032

According to Zion Market Research, the global asthma therapeutics market is projected to attain more than USD 46.83 Billion and grow at a CAGR of 5.4% during the forecast period 2024 – 2032. This is owing to the generic erosion experienced by prominent brands, like Advair and Symbicort. On the contrary, the surging incidence of respiratory diseases along with the demand for affordable treatment alternatives is likely to boost the asthma therapeutics market growth over the estimated period. As per the estimates of the GINA (Global Initiative for Asthma), in 2013, almost 300 million patients worldwide were reported to be affected with this disease and the number is predicted to advance in the upcoming years. This is one of the main reasons for augmenting the adoption of asthma therapeutics globally. Moreover, factors such as increasing indoor & outdoor causative agents counting allergens, pollution, and dust, along with the altering lifestyles that influence the occurrence of asthma are furthermore fueling the asthma therapeutics demand over the forecast period.

Some of the leading players in this market are Philips Healthcare; AstraZeneca Plc; GlaxoSmithKline Plc; Teva Pharmaceutical Industries Ltd.; CareFusion Corporation; Sanofi-Aventis SA; Boehringer Ingelheim GmbH; Sunovion Pharmaceuticals, Inc.; Merck & Co., Inc.; and Roche Diagnostics. These contenders are projected to witness a steady growth mainly owing to the branded drugs approaching their imminent patent expiration dates and the rigorous generic competition in the emerging countries.

Government & Private Funding And Raising Awareness About Healthcare To Boost The Global Asthma Therapeutics Market

The surging prevalence, augmenting environmental pollution, potential late-stage pipeline molecules, launch of novel technologies, and deployment of personalized medicine are expected to drive the market growth over the forecasted period. Funding by the administrative agencies & private organizations, surging healthcare consciousness, and rising economic development in some countries are major driving factors for the global asthma therapeutics market. Factors like patent expiry of best-seller drugs and under-diagnosis of the disease are hampering the asthma therapeutics market growth.

The global asthma therapeutics market is bifurcated on the basis of drug class, route of administration, product, and regional analysis. Based on the drug class, the market is divided into bronchodilators, anti-inflammatory, and combination therapy. Based on the product, the market is divided into inhalers and nebulizers. The inhalers section is subdivided into dry powder inhalers, soft mist inhalers, and metered dose inhalers. Based on the route of administration, the market is segmented into inhaled, oral, and others.

The North America Region Expected To Witness Massive Growth In The Global Asthma Therapeutics Market

Based on geographical analysis, the global asthma therapeutics market is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The market in North America is likely to contribute to the largest market share during the forecasted period. This is due to augmented product launches by prominent players. For example, in February 2018, Teva Pharmaceutical Industries Ltd. introduced its innovative QVAR RediHaler Inhalation Aerosol across the U.S. This aerosol is utilized for controlling & treating of asthma.

Browse the full “Asthma Therapeutics Market - By Drug Class (Bronchodilators, Anti-Inflammatory, And Combination Therapy), By Product (Inhalers And Nebulizers), By Route Of Administration (Inhaled, Oral, And Others), And By Region - Global Industry Perspective, Comprehensive Analysis, And Forecast, 2024 – 2032.” Report at https://www.zionmarketresearch.com/report/asthma-therapeutics-market

The global asthma therapeutics market is segmented as follows:

By drug class:

• Anti-inflammatory
• Combination therapy
• Bronchodilators

By product:

• Inhalers
  • Soft mist inhalers
  • Metered dose inhalers
  • Dry powder inhalers
• Nebulizers

By route of administration:

• Inhaled
• Oral
• Others

By region:

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com